MindMed (MNMD) IPO on Nasdaq: Becomes Second Public Psychedelic Company.

InvestmentU By Amber Deter Apr 27, 2021 at 12:55PM The MindMed IPO is making...
Ehave, Psychedelic Stock Review

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First...

Huge News at Ehave Inc.(EHVVF), our Favorite Psychedelic.

We just finished compiling the 2021 Psychedelic Investor Guide and reviewed 44 companies - in all shapes and sizes. Excluding Johnson &...

Cybin (CLXPF CYBN) Banks $30 Million Overnight.

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares. LIVE QUOTE
Marcus Capone, Psychedelic Stock Review

Incredible Ibogaine Psychedelic’s Testimonial

TIME MAGAZINEIn 2013, Marcus retired from the military. But life as a civilian only made his depression, anger, headaches, anxiety, alcoholism, impulsivity...
Psychedelic Stock Review

Are Psychedelics the New Prozac?

Amidst a national epidemic of opioid abuse, and suicides the need for new therapeutics has gained greater urgency. In it's first step to...

Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright.

Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target.

Atai Life Sciences (ATAI) Founder Christian Angermayer Interview.(VIDEO)

Best Psychedelic related interview we've seen yet. Christian states, "I think ultimately, the total addressable market is 100% of the world population!"

I Use Ketamine for Depression – Here’s How It Works.

FREETHINK: When first manufactured as an anesthetic for humans and animals in 1962, doctors had no intention of prescribing ketamine for depression....
ehave, ehvvf

Ehave (EHVVF) Looks to Power the Psychedelics Revolution

Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days...

Latest article

Revive therapeutics

Our Best Risk to Reward Idea Ever?

Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 pack, 12 Biotech Stocks We Expect to...
Immunix Bio

ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.

Demonstrates 100% Completion of Planned Treatment Cycles. Immix Biopharma, Inc. Wed, January 19, 2022. ImmixBio...
Fuqua Professor David Ridley

Everything You Need to Know About FDA’s Priority Review Vouchers Worth $100’s of Millions.

Never Heard of These 'PRV's' but What a Potential Bonanza for the Recipients. They're transferable - as in they can be...